Drug Evaluation Committee 105th Clinical Evaluation Subcommittee General Meeting (Part 2)-Considering the Future Pharmaceutical Industry from the Perspective of Advances in Digital Technology
Feb 18, 2022
- About us
- About Pharmaceuticals
- Information from the Committee
Information from the Committee Top
- Code Compliance Promotion Committee
- Industry Policy Committee
- Distribution Appropriateness Committee
- Drug Evaluation Committee
- Quality Committee
- Biopharmaceutical Committee
- Regulatory Affairs Committee
- Intellectual Property Committee
- Research and Development Committee
- International Committee
- Public Relations Committee
- Patient Organization Collaboration Promotion Committee
- ICH Project
- APAC Project
- Pharmaceutical Counseling and Response Review Committee
- Environmental Issues Review Committee
- Newsletter
- News Room
- Pharmaceutical Industry Policy Institute
- Patients and the general public (About Pharmaceuticals)
-
Information from the Committee
- Code Compliance Promotion Committee
- Industry Policy Committee
- Distribution Appropriateness Committee
- Drug Evaluation Committee
- Quality Committee
- Biopharmaceutical Committee
- Regulatory Affairs Committee
- Intellectual Property Committee
- Research and Development Committee
- International Committee
- Public Relations Committee
- Patient Organization Collaboration Promotion Committee
- ICH Project
- APAC Project
- Pharmaceutical Counseling and Response Review Committee
- Environmental Issues Review Committee
- About us
- Policies and Activities
-
Voluntary Standards
- Charter of Conduct
- Pharmaceutical Association Code of Practice
- Transparency Guidelines for Relationships between Corporate Activities and Medical Institutions
- Transparency Guidelines for Relationships between Corporate Activities and Patient Groups
- Guidelines for the Preparation of Product Information Summaries for Ethical Drugs (Abbreviated name: Preparation Guidelines)
- Clinical Research
- Basic Philosophy and Action Guidelines on Biodiversity
- Guidelines for Appropriate Competition in the Meetings of the Japan Pharmaceutical Manufacturers Association (JPMA)
- Guidelines for the Promotion of Pharmaceutical Industry
- News Room
-
Pharmaceutical Industry Policy Institute
- Social Media Policy
- Website Terms of Use
- Industry Vision, Policy Recommendations